 |
|
|
| |
Six Years of Treatment With Tenofovir Disoproxil Fumarate for Chronic Hepatitis B Virus Infection Is Safe and Well Tolerated and Associated With Sustained Virological, Biochemical, and Serological Responses With No Detectable Resistance
|
| |
| |
Reported by Jules Levin
AASLD Nov 9-13 2012 Boston
Patrick Marcellin1, Maria Buti2, Edward Gane3, Naoky Tsai4, William Sievert5, Ira M. Jacobson6, George Germanidis7, Phillip Dinh8, John F. Flaherty8,
Kathryn M. Kitrinos8, John G. McHutchison8, Nezam H. Afdhal9
1Hôpital Beaujon, Clichy, France; 2Hospital General Universitari Vall d'Hebron and Ciberehd, Barcelona, Spain; 3Auckland City Hospital, Auckland, New Zealand; 4University of Hawaii at Manoa, Honolulu, HI, United States; 5Monash University and Monash Medical Centre, Melbourne, VIC, Australia; 6Weill Cornell Medical College, New York, NY, United States; 7AHEPA University Hospital, Aristotle University Medical School, Thessaloniki, Greece; 8Gilead Sciences, Inc., Foster City, CA, United States; 9Beth Israel Deaconess Medical Center, Boston, MA, United States
|
| |
|
|
|
|
|
